CLW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CLW is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is technically weak, analyst sentiment is mixed-to-negative, and there are no fresh catalysts. With no AI Stock Picker or SwingMax signal, this is not a strong entry today. If you are impatient and want to act now, the better move is to wait rather than buy here.
Current price is 15.92, just above S1 support at 15.595 and below the pivot at 16.263. The trend is bearish: SMA_200 > SMA_20 > SMA_5, which shows price is trading under a weakening structure. MACD histogram is -0.177 and still negative, while RSI_6 at 42.892 is neutral but not strong enough to signal a reversal. Overall, the chart still favors downside pressure over an immediate breakout.
Clearwater Paper is now a more focused pure-play SBS producer after its tissue exit and Augusta mill acquisition, which simplifies the business. RBC still views the stock as cheap and sees some potential improvement if supply-demand balance tightens, especially from lower imports and grade substitution. Long term, balance sheet flexibility and strategic repositioning are positives.
The industry backdrop remains challenged, with oversupplied SBS markets, limited near-term catalysts, elevated energy/freight costs, and management flagging a tough Q2 with ongoing quarterly inflation of $3M-$5M. The stock trend model also points to weakness over the next week and month.
Latest quarter data was not provided cleanly, but the analyst commentary references Q1 adjusted EBITDA of $1.9M, slightly ahead of estimates, and results were broadly in line. The key takeaway is that the latest quarter showed only modest profitability and ongoing cost pressure rather than strong growth. This is not the kind of financial momentum that supports an aggressive long-term buy right now.
Recent analyst tone has turned more cautious. BofA initiated at Neutral with a $19 target, TD Cowen downgraded to Hold with a $17 target, Truist lowered its target to $12 and kept Hold, while RBC remains Outperform but trimmed its target to $19 and still calls the stock cheap. Wall Street is split, but the majority view is cautious because the business is tied to a difficult industry backdrop with limited near-term catalysts. Overall pros: strategic simplification and cheap valuation; cons: oversupply, cost inflation, and weak earnings visibility.
